Generics A perspective on Indonesia’s booming market for contraceptive products from Hendra Gunawan, managing director of PT Tunggal Idaman Abdi, one of Indonesia’s leading players in the sector. To cope with the growing demand for contraceptive driven by 65 million women of reproductive age, the company is building a second hormone…
Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…
Ireland What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere) is one factor, but it doesn’t end there. Talent: “The first factor is the excellence of the workforce, which is…
Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…
Generics Fergal Murphy, Chairman of the Association of Pharmaceutical Manufacturers in Ireland, discusses with pharamaboardroom.com the difficulties in such a small market and how the industry is adapting to the needs of Ireland by working closely with the government to find the right price point for products and increasing awareness of…
Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…
Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…
Mexico In the late 1990s, Rodrigo Herrera Aspra wanted to commercialize a new anti-acne formulation, and was advised by a friend who was involved in the pharmaceutical industry to hire a group of medical reps. “After thinking on this issue, I concluded there was something wrong with a business model in…
Genzyme - Ireland Mr. Martin, you were appointed as Genzyme’s GM for UK and Ireland last month after having spent a decade at the organization. Robin Kenselaar, Head of Genzyme EMEA, noted that your appointment came at a “key time for the business.” What is your understanding of where this company is going…
ThromboGenics Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud of? At the moment, ThromboGenics basically has one key product, Ocriplasmin, which has recently completed phase-III clinical studies. Initially, this…
Industrial Development Agency - Ireland Mr. O’Leary, when an article in The Guardian last year profiled you and your work, it was titled “Resurrecting the Celtic Tiger.” More recently, Time Magazine put Taoiseach Enda Kenny on its cover, and foretold of a “Celtic Revival.” Is this a time for optimism in the Irish economy? There…
See our Cookie Privacy Policy Here
